Sarah A. Spinler, PharmD, FCCP, FAHA, FASHP, AACC, BCPS (AQ Cardiology)

Anticoagulants are one of the most commonly prescribed medication classes, and the utilization of these agents is on the rise.

The introduction of mavacamten represents a major shift in the treatment of obstructive hypertrophic cardiomyopathy, but raises dosing and drug-drug interaction challenges.

Medication adherence, the extent to which an individual’s behavior corresponds to a health care provider’s recommendations, remains an unaddressed challenge in health care.

Over the last 50 years, revascularization and pharmacotherapeutic innovations have led to significant reductions in major adverse CV events associated with both acute and chronic coronary diseases.

Pharmacists are one of the most accessible health care providers and singularly well positioned to lead efforts in integrating pharmacogenomics testing to improve medication-related outcomes.

Obesity is one of the most common chronic preventable comorbidities affecting adults and children in the United States.

Acute and recurrent pericarditis are the most common pericardial syndromes and represent an etiology of chest pain that is associated with substantial morbidity, decreased quality of life and, rarely, mortality.

Atrial fibrillation is common, affecting approximately 5.2 million patients in 2010 in the United States, and this is projected to increase to 12.1 million in 2030.

Mineralocorticoid receptor antagonists disrupt the renin-angiotensin-aldosterone system and provide beneficial outcomes in several renin-angiotensin-aldosterone system-mediated disease states.

Approximately 52% of patients with HF are categorized as those with a preserved ejection fraction. Hospitalizations in this patient population are continuing to increase.